Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Chandler D. Wilfong
Based on 1 article published since 2008
||||

Between 2008 and 2019, Chandler D. Wilfong wrote the following article about Melanoma.
 
+ Citations + Abstracts
1 Article Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas. 2016

Kim, Minhyung / Neznanov, Nickolay / Wilfong, Chandler D / Fleyshman, Daria I / Purmal, Andrei A / Haderski, Gary / Stanhope-Baker, Patricia / Burkhart, Catherine A / Gurova, Katerina V / Gudkov, Andrei V / Skitzki, Joseph J. ·Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York. · Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York. · Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York. · Cleveland BioLabs, Inc., Buffalo, New York. · Incuron, LLC, Buffalo, New York. · Buffalo BioLabs, LLC, Buffalo, New York. · Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York. joseph.skitzki@roswellpark.org. ·Cancer Res · Pubmed #27680682.

ABSTRACT: Isolated limb perfusion (ILP) with the chemotherapeutic agent melphalan is an effective treatment option for extremity in-transit melanoma but is toxic and technically challenging to deliver locoregionally. CBL0137 is an experimental clinical drug with broad anticancer activity in animal models, owing to its ability to bind DNA in a nongenotoxic manner and inactivate the FACT chromatin modulator essential for tumor cell viability. Here, we report that CBL0137 delivered by ILP in a murine melanoma model is as efficacious as melphalan, displaying antitumor activity at doses corresponding to only a fraction of the systemic MTD of CBL0137. The ability to bind DNA quickly combined with a favorable safety profile made it possible to substitute CBL0137 in the ILP protocol, using an intra-arterial infusion method, to safely achieve effective tumor suppression. Our findings of a preclinical proof of concept for CBL0137 and its administration via intra-arterial infusion as a superior treatment compared with melphalan ILP allows for locoregional treatment anywhere a catheter can be placed. Cancer Res; 76(22); 6620-30. ©2016 AACR.